Figures & data
Table 1. Characteristics of the 33 patients who underwent USgHIFU, and mean volumes before treatment.
Table 2. Clinical parameters included in the UFS-QOL [Citation11].
Figure 1. Plain US images collected (A) before and (B) after HIFU treatment show the difference in fibroid ecogenicity. In (B) disomogeneous hyperchoic changes of treated fibroid are visible.
![Figure 1. Plain US images collected (A) before and (B) after HIFU treatment show the difference in fibroid ecogenicity. In (B) disomogeneous hyperchoic changes of treated fibroid are visible.](/cms/asset/68ccad95-015e-4817-934e-0383c938d39b/ihyt_a_1004134_f0001_c.jpg)
Figure 2. CEUS imaging before (A) and after (B) USgHIFU of 48 mm highly perfused uterine fibroma (*). In (B) CEUS shows a complete devascularisation of the treated fibroma. Arrow = left common femoral vein; arrowhead = bowel loop.
![Figure 2. CEUS imaging before (A) and after (B) USgHIFU of 48 mm highly perfused uterine fibroma (*). In (B) CEUS shows a complete devascularisation of the treated fibroma. Arrow = left common femoral vein; arrowhead = bowel loop.](/cms/asset/077388b6-939d-4338-8357-0c453bec9966/ihyt_a_1004134_f0002_c.jpg)
Figure 3. CEUS imaging during USgHIFU of a 75-mm highly perfused uterine fibroma shows a still highly perfused tissue (arrowheads) around the central, already treated, devascularised area (*).
![Figure 3. CEUS imaging during USgHIFU of a 75-mm highly perfused uterine fibroma shows a still highly perfused tissue (arrowheads) around the central, already treated, devascularised area (*).](/cms/asset/05a24f01-b5fe-438c-9adf-223aab2d52ff/ihyt_a_1004134_f0003_c.jpg)